According to the present results, the blockade of P2X4 receptors allows an effective control of experimental intestinal inflammation, and novel and selective P2X4 antagonists can provide a basis for development of anti-inflammatory drugs suitable for treatment of IBD. Here, P2RX4 is linked to inflammatory bowel disease.